Today is international #childhoodcancerday 🎗️ We work to develop new strategies against this disease. Every breakthrough brings us closer to a future where it's preventable, treatable, and curable. 🔬 Research changes lives - share this message and help raise awareness! 📢🧡

It's David Tennant's world, we're just living in it... #EEBAFTAs #DavidTennant

“Es importante educar a la siguiente generación. Las enfermedades no se solucionan hoy ni mañana, siempre van a dar problemas que necesitaremos solucionar”. - Juan Fueyo gracias por venir a hablar con la próxima generación de científicos sobre la investigación en #cáncer 🔬

One month ago, we had the pleasure of hosting the 4th edition of AdenoNet! 🧪We were proud to see our thesis student Daniel Palacios present his project and nailed it!!! Huge thanks to everyone who joined us — we had a great time and learned so much! 💡✨

📢 ¡Nueva publicación en la que ha participado Sandra Morales, una de nuestras estudiantes de tesis! 👏 Nos hace mucha ilusión verla contribuir a trabajos tan interesantes. ¡Enhorabuena a todo el equipo! 🧬✨

😜 Lo estabais esperando... Nuevo +3 PD: Herrando ya ha aprendido a hacerlo 😂

Our lab has been at #pedSNO2025 and we are excited to share what we’ve been working on this year. A quick thread on our team’s contributions 👇

We’re very proud of our PhD student Sara 🦋! She had the opportunity to give an oral presentation at #pedSNO2025 sharing part of her work on the combination of Delta-24-RGD and TIM-3 blockade to enhance oncolytic virotherapy in DMGs. Great job! 👏🏼🧠

🦠 Poster 1 – Improving oncolytic virotherapy by blocking CD47-SIRPα axis with single-domain antibodies in diffuse midline gliomas. Presented by Daniel Palacios, co-supervised with #MarcGarciaMoure and supported by Fundación Blanca Morell

Exciting news! We are pleased to share that our PhD student Daniel Palacios has been awarded a prestigious PhD fellowship from Fundación Blanca Morell to research new oncolytic virotherapy strategies for DMG. Huge congratulations! 🎉👏

We are thrilled to share our latest work, led by Sara Labiano , on the potential of combining the oncolytic virus Delta-24-RGD with a CD40 agonist to treat diffuse midline gliomas (#DMG). Published in Cell Reports Medicine ! (1/14) 🔗doi.org/10.1016/j.xcrm…

Esto qué sentido ha tenido?

Yesterday we explained our posters at #ESGCT2025 — if you missed them, don’t worry, you can still see them today! Here’s a look at our latest research 👇

🧠 Poster 1 (P1069) - Combination of Delta-24-RGD and TIM-3 blockade to enhance oncolytic virotherapy in DMGs. Presented by @Saranuin01 and supported by Ministerio de Ciencia, Innovación y Universidades

🦠 Poster 2 (P1071) – Improving oncolytic virotherapy by blocking CD47-SIRPα axis with single-domain antibodies in diffuse midline gliomas. Presented by Daniel Palacios, co-supervised by #MarcGarciaMoure and supported by Fundación Blanca Morell

Thanks to the organizers and everyone stopping by to chat! Looking forward to the next one! #ESGCT2025 #SETGYC2025

☢️ Poster 1 – Exploiting conventional type 1 dendritic cells as a new therapeutic strategy to limit neurocognitive sequelae after pediatric brain tumor radiotherapy. A poster from our PhD Student Javier Marco Sanz, co-supervised with Sara Labiano

🧠 Poster 2 – Cognitive and motor effects of TIM-3 blockade in diffuse midline glioma murine models. A work presented by our PhD Student #SandraMorales and supported by Ministerio de Ciencia, Innovación y Universidades

First, our PhD Student #SandraMorales gave an amazing talk about how the therapeutic inhibition of TIM-3 supports neurological function post-tumor clearance in DMG preclinical models. Great job!

Secondly, our PI marta m alonso gave an exciting talk regarding how to get the transition right in the treatment for Adolescents and Young Adults with CNS tumors. A relevant problem that needs to be adressed.